



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07D 211/54, 401/10, A61K 31/445, A61P 25/00		A1	(11) International Publication Number: WO 00/43362 (43) International Publication Date: 27 July 2000 (27.07.00)
(21) International Application Number: PCT/GB00/00153 (22) International Filing Date: 11 January 2000 (11.01.00)		(74) Agent: THOMPSON, John; Merck & Co., Inc., European Patent Dept., Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB).	
(30) Priority Data: 9901147.0 19 January 1999 (19.01.99) GB		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(71) Applicant (<i>for all designated States except US</i>): MERCK SHARP & DOHME LIMITED [GB/GB]; Hertford Road, Hoddesdon, Hertfordshire EN11 9BU (GB). (72) Inventors; and (75) Inventors/Applicants (<i>for US only</i>): BLURTON, Peter [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). BURKAMP, Frank [DE/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). CHENG, Susan, Koon-Fung [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). FLETCHER, Stephen, Robert [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). MACLEOD, Angus, Murray [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). VAN NIEL, Monique, Bodil [NL/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB).		Published <i>With international search report.</i>	
(54) Title: PHENYLSULPHONYL DERIVATIVES AS 5-HT RECEPTOR LIGANDS			
(57) Abstract A class of phenylsulphonyl derivatives wherein the sulphonyl moiety is also attached to an <i>N</i> -arylalkyl-substituted azetidine, pyrrolidine or piperidine ring are selective antagonists of the human 5-HT _{2A} receptor and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of adverse conditions of the central nervous system, including schizophrenia and depression.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

**PHENYLSULPHONYL DERIVATIVES AS 5-HT RECEPTOR
LIGANDS**

The present invention relates to a class of sulphonyl derivatives
5 which act on serotonin receptors (also known as 5-hydroxytryptamine or
5-HT receptors). More particularly, the invention concerns
phenylsulphonyl derivatives wherein the sulphonyl moiety is also attached
to an *N*-aryalkyl-substituted azetidine, pyrrolidine or piperidine ring.
These compounds are selective antagonists of the human 5-HT_{2A} receptor
10 and are therefore useful as pharmaceutical agents, especially in the
treatment and/or prevention of adverse conditions of the central nervous
system, including psychotic disorders such as schizophrenia.

Schizophrenia is a disorder which is conventionally treated with
drugs known as neuroleptics. In many cases, the symptoms of
15 schizophrenia can be treated successfully with so-called "classical"
neuroleptic agents such as haloperidol. Classical neuroleptics generally
are antagonists at dopamine D₂ receptors.

Notwithstanding their beneficial antipsychotic effects, classical
neuroleptic agents such as haloperidol are frequently responsible for
20 eliciting acute extrapyramidal symptoms (movement disorders) and
neuroendocrine (hormonal) disturbances. These side-effects, which plainly
detract from the clinical desirability of classical neuroleptics, are believed
to be attributable to D₂ receptor blockade in the striatal region of the
brain.

25 The compound (+)- α -(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)-
ethyl]-4-piperidinemethanol (also known as MDL-100,907) is described in
WO 91/18602. In preclinical studies, MDL-100,907 failed to induce
catalepsy and failed to block apomorphine-induced stereotyped behaviour
in animal models, strongly suggesting that this compound would be free
30 from any liability to cause extrapyramidal side-effects. MDL-100,907 is
currently undergoing clinical trials in schizophrenic patients and has

- 2 -

demonstrated efficacy in a multicentre, placebo-controlled study for antipsychotic potential, with no neurological adverse effects.

Pharmacologically, MDL-100,907 has been shown to be a potent antagonist of human 5-HT_{2A} receptors, whilst being essentially devoid of activity at the human dopamine D₂ receptor. It is accordingly believed that compounds which can interact selectively with the 5-HT_{2A} receptor relative to the dopamine D₂ receptor will display the beneficial level of antipsychotic activity associated with 5-HT_{2A} receptor antagonism, whilst minimizing or even avoiding the extrapyramidal and other side-effects arising from an interaction with dopamine D₂ receptors.

The compounds of the present invention are potent antagonists of the human 5-HT_{2A} receptor, and are accordingly of benefit in the treatment and/or prevention of psychotic disorders such as schizophrenia. The compounds of the invention may display more effective binding to the human 5-HT_{2A} receptor than to the human dopamine D₂ receptor, and they can therefore be expected to manifest fewer side-effects than compounds which do not discriminate in their binding affinity as between 5-HT_{2A} and D₂ receptors.

By virtue of their potent human 5-HT_{2A} receptor antagonist activity, the compounds of the present invention are also effective in the treatment of neurological conditions including depression, anxiety, panic disorder, obsessive-compulsive disorder, pain, sleep disorders such as insomnia, eating disorders such as anorexia nervosa, and dependency or acute toxicity associated with narcotic agents such as LSD or MDMA; and moreover are beneficial in controlling the extrapyramidal symptoms associated with the administration of neuroleptic agents. They may further be effective in the lowering of intraocular pressure and may therefore be beneficial in treating glaucoma (cf. T. Mano *et al.* and H. Takanaka *et al.*, *Investigative Ophthalmology and Visual Science*, 1995, vol. 36, pages 719 and 734 respectively).

- 3 -


Being 5-HT_{2A} receptor antagonists, the compounds of the present invention may also be beneficial in preventing or reducing the toxic symptoms associated with the intake of ergovaline in animals consuming *Acromonium coenophialum* infected tall fescue (cf. D. C. Dyer, *Life Sciences*, 1993, 53, 223-228).

Various classes of compounds containing *inter alia* a sulphonyl moiety, which are stated to have activity as antipsychotic agents, are described in WO 96/35666, EP-A-0261688, and US Patents 4,218,455 and 4,128,552. A further series of compounds, containing *inter alia* a piperidinyl-sulphonyl-indole moiety, is described in US Patent 5,418,242, and alleged to possess analgesic properties. DE-A-3901735 relates to the use of a class of compounds containing *inter alia* a sulphonylpyridine moiety in the treatment of depression. None of these publications, however, discloses or suggests the particular class of phenylsulphonyl derivatives provided by the present invention.

The compounds according to the present invention are potent and selective 5-HT_{2A} receptor antagonists having a human 5-HT_{2A} receptor binding affinity (K_i) of 100 nM or less, typically of 50 nM or less and preferably of 10 nM or less. The compounds of the invention may possess at least a 10-fold selective affinity, suitably at least a 20-fold selective affinity and preferably at least a 50-fold selective affinity, for the human 5-HT_{2A} receptor relative to the human dopamine D₂ receptor.

The present invention provides a compound of formula I, or a salt thereof:

25



(I)

wherein

Z represents hydrogen, halogen, cyano, nitro, trifluoromethyl, trifluoromethoxy, -OR^a, -SR^a, -SOR^a, -SO₂R^a, -SO₂NR^aR^b, -NR^aR^b,
5 -NR^aCOR^b, -NR^aCO₂R^b, -COR^a, -CO₂R^a or -CONR^aR^b; or
Z represents an optionally substituted five-membered heteroaromatic ring selected from furan, thiophene, pyrrole, oxazole, thiazole, isoxazole, isothiazole, imidazole, pyrazole, oxadiazole, thiadiazole, triazole and tetrazole; or
10 Z represents an optionally substituted six-membered heteroaromatic ring selected from pyridine, pyrazine, pyrimidine and pyridazine;
R^a and R^b independently represent hydrogen or C₁₋₆ alkyl; or R^a and R^b, when linked through a nitrogen atom, together represent the residue of
15 an azetidine, pyrrolidine, piperidine or morpholine ring;
E represents a chemical bond or a straight or branched alkylene chain containing from 1 to 4 carbon atoms, optionally incorporating an oxygen atom to form an ether linkage;
M represents the residue of an azetidine, pyrrolidine or piperidine ring;
20 R¹ represents an optionally substituted aryl(C₂₋₄)alkyl group; and
R² represents hydrogen or halogen.
Where Z in the compounds of formula I above represents a five-membered heteroaromatic ring, this ring may be optionally substituted by one or, where possible, two substituents. As will be appreciated, where Z represents an oxadiazole, thiadiazole or tetrazole ring, only one substituent will be possible; otherwise, one or two optional substituents may be accommodated around the five-membered heteroaromatic ring Z.
25 Where Z in the compounds of formula I above represents a six-membered heteroaromatic ring, this ring may be optionally substituted by one or more substituents, typically by one or two substituents.

Examples of suitable substituents on the five-membered or six-membered heteroaromatic ring as specified for Z include halogen, cyano, trifluoromethyl, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, amino, C₁₋₆ alkylamino and di(C₁₋₆)alkylamino, especially methyl.

5 The aryl(C₂₋₄)alkyl group R¹ may be optionally substituted by one or more substituents. Suitably, the aryl(C₂₋₄)alkyl group R¹ is unsubstituted, or substituted by one, two or three substituents. More particularly, the aryl(C₂₋₄)alkyl group R¹ may be unsubstituted, or substituted by one or two substituents. Any optional substitution on the aryl(C₂₋₄)alkyl group R¹ will suitably be on the aryl moiety thereof, although substitution on the alkyl moiety thereof is an alternative possibility.

10 Representative examples of optional substituents on the group R¹ include halogen, nitro, trifluoromethyl, trifluoromethoxy, C₁₋₆ alkyl, keto, hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkylthio or di(C₁₋₆)alkylamino.

15 Illustrative examples of optional substituents on the group R¹ include halogen, nitro, trifluoromethyl, trifluoromethoxy, C₁₋₆ alkyl, hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkylthio or di(C₁₋₆)alkylamino.

20 As used herein, the expression "C₁₋₆ alkyl" includes methyl and ethyl groups, and straight-chained or branched propyl, butyl, pentyl and hexyl groups. Particular alkyl groups are methyl, ethyl, *n*-propyl, isopropyl and *tert*-butyl. Derived expressions such as "C₁₋₆ alkoxy", "C₁₋₆ alkylthio" and "C₁₋₆ alkylamino" are to be construed accordingly.

Typical aryl groups include phenyl and naphthyl, preferably phenyl.

25 The expression "aryl(C₂₋₄)alkyl" as used herein includes phenylethyl, phenylpropyl and naphthylethyl, especially phenylethyl.

The term "halogen" as used herein includes fluorine, chlorine, bromine and iodine, especially fluorine or chlorine.

30 For use in medicine, the salts of the compounds of formula I will be pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds according to the invention or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable

salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, 5 fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable 10 organic ligands, e.g. quaternary ammonium salts.

Where the compounds according to the invention have at least one asymmetric centre, they may accordingly exist as enantiomers. Where the compounds according to the invention possess two or more asymmetric 15 centres, they may additionally exist as diastereoisomers. It is to be understood that all such isomers and mixtures thereof in any proportion are encompassed within the scope of the present invention.

Typically, the substituent Z in the compounds of formula I above represents hydrogen, halogen, cyano, -NR^aCOR^b, -CO₂R^a or -CONR^aR^b; or 20 an optionally substituted five-membered ring as specified above.

Suitably, the substituent Z represents hydrogen, cyano, -NR^aCOR^b or -CONR^aR^b; or an optionally substituted five-membered ring as specified above.

Suitably, R^a represents hydrogen or methyl, especially hydrogen. 25 Suitably, R^b represents hydrogen or methyl, especially hydrogen.

Where the group Z represents an optionally substituted five-membered heteroaromatic ring, this is suitably an imidazole, pyrazole, 1,2,3-triazole, 1,2,4-triazole or tetrazole ring, any of which may be optionally substituted, typically by methyl.

30 Specific values for the group Z include hydrogen, bromo, cyano, acetylamino, methoxycarbonyl, carboxamido, imidazol-1-yl, pyrazol-1-yl,

1,2,3-triazol-1-yl, 1,2,4-triazol-1-yl, 1-methyl-1,2,4-triazol-5-yl, tetrazol-1-yl and 2-methyltetrazol-5-yl.

Particular values for the group Z include hydrogen, cyano, acetylamino, carboxamido, imidazol-1-yl, pyrazol-1-yl, 1,2,3-triazol-1-yl, 5 1,2,4-triazol-1-yl, 1-methyl-1,2,4-triazol-5-yl, tetrazol-1-yl and 2-methyltetrazol-5-yl.

One specific value of Z is carboxamido.


Another specific value of Z is cyano.

Where E represents a straight or branched alkylene chain, this may 10 be, for example, methylene, ethylene, 1-methylethylene, propylene, 2-methylpropylene or butylene. The alkylene chain E may optionally incorporate an oxygen atom, thereby forming an ether linkage. Moreover, E may represent a chemical bond such that the moiety Z is attached directly to the phenyl ring as depicted in formula I above.

15 Preferably, E represents a chemical bond or a methylene linkage.

In a specific embodiment, E represents a chemical bond.


In one particular configuration, the moiety Z-E- in the compounds of formula I is attached at the *para* position relative to the sulphonyl group, 20 in which case the present invention suitably provides a compound of formula IA, or a salt thereof:



(IA)

wherein Z, E, M, R^1 and R^2 are as defined above.

25 The moiety M preferably represents the residue of a piperidine ring, in which case the present invention suitably provides a compound of formula IB, or a salt thereof:



wherein Z, E, R¹ and R² are as defined above.

5 Suitably, R¹ represents optionally substituted phenylethyl or optionally substituted phenylpropyl. In addition, R¹ may represent optionally substituted naphthylethyl.

10 Preferably, R¹ represents phenylethyl, which may be unsubstituted, or substituted by one or more substituents. Typically, the phenylethyl group R¹ will be unsubstituted, or substituted by one, two or three (especially one or two) substituents. In a particular embodiment, R¹ represents disubstituted phenylethyl.

15 Examples of specific substituents on the group R¹ include fluoro, chloro, bromo, iodo, nitro, trifluoromethyl, methyl, keto, hydroxy, methoxy, methylthio and dimethylamino.

Particular examples of optional substituents on R¹ include fluoro, chloro, bromo, iodo, nitro, trifluoromethyl, methyl, hydroxy, methoxy, methylthio and dimethylamino.

20 Specific examples of optional substituents on R¹ include fluoro, chloro and keto, especially fluoro.

Representative values of R¹ include phenylethyl, fluoro-phenylethyl, chloro-phenylethyl, bromo-phenylethyl, iodo-phenylethyl, difluoro-phenylethyl, dichloro-phenylethyl, (chloro)(fluoro)-phenylethyl, (fluoro)-(trifluoromethyl)-phenylethyl, (bromo)(methoxy)-phenylethyl, trifluoro-phenylethyl, nitro-phenylethyl, methyl-phenylethyl, hydroxy-phenylethyl, methoxy-phenylethyl, dimethoxy-phenylethyl, (hydroxy)(methoxy)-

- 9 -

phenylethyl, (hydroxy)(dimethoxy)-phenylethyl, trimethoxy-phenylethyl, methylthio-phenylethyl, dimethylamino-phenylethyl, phenylpropyl, hydroxy-phenylpropyl and naphthylethyl. Additional values of R¹ include fluorophenyl-oxoethyl and chlorophenyl-oxoethyl.

5 Typical values of R¹ include phenylethyl, fluoro-phenylethyl, chloro-phenylethyl, difluoro-phenylethyl, fluorophenyl-oxoethyl and chlorophenyl-oxoethyl.

Particular values of R¹ include phenylethyl, fluoro-phenylethyl, chloro-phenylethyl and difluoro-phenylethyl.


10 Suitably, R¹ may represent 2-phenylethyl, 2-fluoro-2-phenylethyl, 2-(4-fluorophenyl)ethyl, 2-(2-chlorophenyl)ethyl, 2-(2,4-difluorophenyl)ethyl, 2-(4-fluorophenyl)-2-oxoethyl or 2-(4-chlorophenyl)-2-oxoethyl.

One specific value of R¹ is 2-(2,4-difluorophenyl)ethyl.

Another specific value of R¹ is 2-(4-fluorophenyl)-2-oxoethyl.

15 Suitably, R² represents hydrogen or fluoro, especially hydrogen.

A particular sub-class of compounds according to the invention is represented by the compounds of formula IIA, and salts thereof:



(IIA)

20

wherein

Z and E are as defined with reference to formula I above;

- 10 -

R^{11} and R^{12} independently represent hydrogen, halogen, nitro, trifluoromethyl, C₁₋₆ alkyl, hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkylthio or di(C₁₋₆)alkylamino;

5 R^{13} represents hydrogen and R^{14} represents hydrogen or fluoro, or
 R^{13} and R^{14} together represent keto; and

R^{21} represents hydrogen or fluoro.

Suitably, R^{11} represents hydrogen, fluoro, chloro or methoxy, especially hydrogen or fluoro.

10 Suitably, R^{12} represents hydrogen, fluoro, chloro, bromo, iodo, nitro, trifluoromethyl, methyl, hydroxy, methoxy, methylthio or dimethylamino. More particularly, R^{12} may represent hydrogen, fluoro or chloro.

In one embodiment of the compounds of formula IIA above, R^{13} represents hydrogen and R^{14} represents hydrogen or fluoro.


15 In another embodiment of the compounds of formula IIA, R^{13} and R^{14} together represent keto.

Suitably, R^{13} and R^{14} are both hydrogen.

Suitably, R^{21} is hydrogen.

Another sub-class of compounds according to the invention is represented by the compounds of formula IIB, and salts thereof:


20



(IIB)

wherein Z, E and R¹ are as defined with reference to formula I above; and R²¹ is as defined with reference to formula IIA above.

25 A particular subset of the compounds of formula IIA and IIB above is represented by the compounds of formula IIC, and salts thereof:



(IIC)

wherein Z, E, R¹¹, R¹², R¹³, R¹⁴ and R²¹ are as defined above.

In one embodiment of the compounds of formula IIC above, R¹³ and
5 R¹⁴ are both hydrogen.

Specific compounds within the scope of the present invention
include:

- 4-(4-cyanophenylsulphonyl)-1-[2-(2,4-difluorophenyl)ethyl]piperidine;
- 4-(4-acetylaminophenylsulphonyl)-1-[2-(2,4-difluorophenyl)ethyl]-
10 piperidine;
- 4-(4-cyano-3-fluorophenylsulphonyl)-1-[2-(2,4-difluorophenyl)ethyl]-
piperidine;
- 1-[2-(2,4-difluorophenyl)ethyl]-4-[4-(1,2,4-triazol-1-yl)phenylsulphonyl]-
piperidine;
- 15 1-[2-(2,4-difluorophenyl)ethyl]-4-[4-(imidazol-1-yl)phenylsulphonyl]-
piperidine;
- 1-[2-(2,4-difluorophenyl)ethyl]-4-[4-(pyrazol-1-yl)phenylsulphonyl]-
piperidine;
- 1-[2-(2,4-difluorophenyl)ethyl]-4-[4-(1,2,3-triazol-1-yl)phenylsulphonyl]-
20 piperidine;
- 4-(4-carboxamidophenylsulphonyl)-1-[2-(2,4-difluorophenyl)ethyl]-
piperidine;
- 4-(4-carboxamido-3-fluorophenylsulphonyl)-1-[2-(2,4-difluorophenyl)ethyl]-
piperidine;

- 12 -

1-[2-(2,4-difluorophenyl)ethyl]-4-[4-(2-methyltetrazol-5-yl)-phenylsulphonyl]piperidine;

1-[2-(2,4-difluorophenyl)ethyl]-4-[4-(1-methyl-1,2,4-triazol-5-yl)-phenylsulphonyl]piperidine;

5 1-[2-(2,4-difluorophenyl)ethyl]-4-[4-(tetrazol-1-ylmethyl)phenylsulphonyl]-piperidine;

4-(4-carboxamidophenylsulphonyl)-1-(2-phenylethyl)piperidine;

4-(4-carboxamidophenylsulphonyl)-1-[2-(4-fluorophenyl)ethyl]piperidine;

4-(4-carboxamidophenylsulphonyl)-1-[2-(2-chlorophenyl)ethyl]piperidine;

10 4-(4-carboxamidophenylsulphonyl)-1-(2-fluoro-2-phenylethyl)piperidine;

1-[2-(2,4-difluorophenyl)ethyl]-4-phenylsulphonylpiperidine;

4-(3-carboxamidophenylsulphonyl)-1-[2-(2,4-difluorophenyl)ethyl]-piperidine;

4-(4-bromophenylsulphonyl)-1-[2-(4-fluorophenyl)-2-oxoethyl]piperidine;

15 4-(4-cyanophenylsulphonyl)-1-[2-(4-fluorophenyl)-2-oxoethyl]piperidine;

1-[2-(4-fluorophenyl)-2-oxoethyl]-4-phenylsulphonylpiperidine;

1-[2-(4-chlorophenyl)-2-oxoethyl]-4-phenylsulphonylpiperidine;

and salts thereof.

The invention also provides pharmaceutical compositions comprising one or more of the compounds according to this invention in association with a pharmaceutically acceptable carrier. Preferably these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. Alternatively, the compositions may be presented in a form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection. An erodible polymer containing the active ingredient may be envisaged. For preparing

solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tabletting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. Favoured unit dosage forms contain from 1 to 100 mg, for example 1, 2, 5, 10, 25, 50 or 100 mg, of the active ingredient. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.


The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for

aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.

In the treatment of schizophrenia, a suitable dosage level is about 5 0.01 to 250 mg/kg per day, preferably about 0.05 to 100 mg/kg per day, and especially about 0.05 to 5 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day.

If desired, the compounds according to this invention may be co-administered with another anti-schizophrenic medicament, for example 10 one producing its effects *via* dopamine D₂ and/or D₄ receptor subtype blockade. In such circumstances, an enhanced anti-schizophrenic effect may be envisaged without a corresponding increase in side-effects such as those caused by, for example, D₂ receptor subtype blockade; or a comparable anti-schizophrenic effect with reduced side-effects may 15 alternatively be envisaged. Such co-administration may be desirable where a patient is already established on an anti-schizophrenic treatment regime involving conventional anti-schizophrenic medicaments. Suitable anti-schizophrenic medicaments of use in combination with the compounds according to the present invention include haloperidol, chlorpromazine, 20 mesoridazine, thioridazine, acetophenazine, fluphenazine, perphenazine, trifluoperazine, chloroprothixene, thiothixene, clozapine, olanzapine, pimozide, molindone, loxapine, sulpiride, risperidone, xanomeline, fananserin and ziprasidone, and pharmaceutically acceptable salts thereof.

The compounds according to the present invention may be prepared 25 by a process which comprises attachment of the R¹ moiety to a compound of formula III:



wherein Z, E, M and R² are as defined above; by conventional means including N-alkylation.

5 Attachment of the R¹ moiety to the compounds of formula III may conveniently be effected by standard alkylation techniques. One example thereof comprises treatment with an aryl(C₂₋₄)alkyl halide, especially a bromide derivative R¹-Br such as 2-phenylethyl bromide or 2-(2,4-difluorophenyl)ethyl bromide, typically under basic conditions, e.g.

10 potassium carbonate or caesium carbonate, in a solvent such as acetonitrile or *N,N*-dimethylformamide, suitably at an elevated temperature and optionally in the presence of sodium iodide. Another example comprises treatment of the compound of formula III with an aryl(C₂₋₄)alkyl mesylate R¹-OSO₂CH₃ such as 2-phenylethyl

15 methanesulphonate, typically in the presence of sodium carbonate and sodium iodide, in a suitable solvent such as 1,2-dimethoxyethane.

Alternatively, the R¹ moiety may conveniently be attached by reductive alkylation, which may be accomplished in a single step, or as a two-step procedure. The single-step approach, for the preparation of a


20 compound of formula I wherein R¹ corresponds to a group of formula -CH₂R^{1a}, suitably comprises treating the required compound of formula III as defined above with the appropriate aldehyde of formula R^{1a}-CHO, e.g. phenylacetaldehyde, in the presence of a reducing agent such as sodium cyanoborohydride. In a typical two-step procedure, a carboxylic acid

25 derivative of formula R^{1a}-CO₂H is condensed with the required compound of formula III, suitably in the presence of a condensing agent such as (i)

bis(2-oxo-3-oxazolidinyl)phosphinic chloride and triethylamine, or (ii) 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 1-hydroxybenzotriazole hydrate, to afford a compound corresponding to formula I wherein R¹ represents -COR^{1a}; the carbonyl group thereof can then be reduced, for example by treatment with borane-tetrahydrofuran complex, or with diisobutylaluminium hydride, and the required compound of formula I thereby obtained.

The compounds of formula III above may be prepared by oxidation of the corresponding compound of formula IV:

10




(IV)

wherein Z, E, M and R² are as defined above, and R^p represents an amino-protecting group; with subsequent removal of the amino-protecting group 15 R^p.

The amino-protecting group R^p in the compounds of formula IV is suitably a carbamoyl moiety such as *tert*-butoxycarbonyl (BOC), which can readily be removed as required by treatment under acidic conditions, e.g. in refluxing methanolic hydrochloric acid.

20

Similarly, the compounds according to the invention may be prepared by a process which comprises oxidizing a compound of formula V:




(V)


wherein Z, E, M, R¹ and R² are as defined above.

Oxidation of the compounds of formula IV or V may conveniently be accomplished by treating the appropriate substrate with an oxidizing agent. Typical oxidizing agents of use in this transformation include *meta*-chloroperbenzoic acid and Oxone®. In an alternative procedure, compound IV or V may be oxidized by treatment with ruthenium(IV) oxide and sodium periodate in a suitable solvent which may typically comprise a mixture of carbon tetrachloride and aqueous acetonitrile.

The intermediates of formula IV and V may be prepared by reacting a compound of formula VI with a compound of formula VII:



(VI)



(VII)

wherein Z, E, M and R² are as defined above, R^{1b} represents an amino-protecting group R^p or corresponds to the moiety R¹ as defined above, and L¹ represents a suitable leaving group.

The leaving group L¹ in the compounds of formula VII above suitably represents a C₁₋₄ alkylsulphonyloxy group such as methanesulphonate (mesylate), in which case the desired intermediate of formula VII can be prepared from the corresponding precursor compound of formula VII wherein L¹ represents hydroxy by mesylation under standard conditions.

The reaction between compounds VI and VII is conveniently effected in a solvent such as acetonitrile, generally in the presence of a base such as potassium carbonate, suitably at an elevated temperature which might typically be the reflux temperature of the solvent employed.

Where they are not commercially available, the starting materials of formula VI may be prepared by procedures analogous to those described in the accompanying Examples, or by standard methods well known from the art.

5 It will be appreciated that any compound of formula I initially obtained from any of the above processes may, where appropriate, subsequently be elaborated into a further desired compound of formula I using techniques known from the art. For example, a compound of formula I initially obtained wherein the moiety Z-E- represents bromo

10 may be converted into the corresponding compound of formula I wherein the moiety Z-E- represents cyano by treatment with copper(I) cyanide in the presence of 1-methyl-2-pyrrolidinone (NMP), or with zinc cyanide in the presence of tetrakis(triphenylphosphine)palladium(0). The resulting compound of formula I wherein the moiety Z-E- represents cyano thereby

15 obtained may in turn be converted into the corresponding compound of formula I wherein the moiety Z-E- represents carboxamido by heating in mineral acid, e.g. 85% sulphuric acid at 100°C, or by treatment with potassium trimethylsilanolate, typically in tetrahydrofuran at reflux.

Alternatively, a compound of formula I initially obtained wherein the

20 moiety Z-E- represents bromo may be converted directly into the corresponding compound of formula I wherein the moiety Z-E- represents carboxamido by heating under a carbon monoxide atmosphere in the presence of 1,1,1,3,3,3-hexamethyldisilazane, diisopropylamine, palladium(II) acetate and 1,3-bis(diphenylphosphino)propane. Where, for

25 example, the moiety Z-E- in the compounds of formula I represents an optionally substituted N-linked pyrrole, imidazole, pyrazole, triazole or tetrazole moiety, e.g. imidazol-1-yl, pyrazol-1-yl, 1,2,3-triazol-1-yl or 1,2,4-triazol-1-yl, these compounds may be prepared by treating the corresponding compound of formula I wherein Z-E- represents bromo with

30 the appropriate optionally substituted pyrrole, imidazole, pyrazole, triazole or tetrazole derivative, in the presence of copper bronze and

sodium hydride, typically with heating in NMP. Where, for example, the moiety Z-E- in the compounds of formula I represents an optionally substituted C-linked five-membered heteroaromatic ring, e.g. 2-methyltetrazol-5-yl or 1-methyl-1,2,4-triazol-5-yl, these compounds may be 5 prepared by reacting the corresponding compound of formula I wherein Z-E- represents bromo with a tributylstannyl derivative of the appropriate heteroaromatic compound, e.g. 2-methyl-5-tributylstannyltetrazole or 1-methyl-5-tributylstannyl-1,2,4-triazole, in the presence of a transition metal catalyst such as tetrakis(triphenylphosphine)palladium(0), typically 10 with heating in a solvent such as *N,N*-dimethylformamide. A compound of formula I wherein, for example, Z represents a tetrazol-1-yl moiety and E is methylene may be prepared from the corresponding compound of formula I wherein the moiety Z-E- represents hydroxymethyl, by mesylation under standard conditions followed by displacement of the 15 mesyl group by treatment with tetrazole, typically in the presence of sodium iodide and a base such as caesium carbonate; the compound of formula I wherein Z-E- represents hydroxymethyl may suitably be prepared by diisobutylaluminium hydride (DIBAL-H) reduction of the corresponding compound of formula I wherein Z-E- represents a C₂₋₆ alkoxy carbonyl group, e.g. methoxycarbonyl, which in turn may be 20 prepared by treatment of the corresponding compound of formula I wherein Z-E- represents bromo with 1,1'-bis(diphenylphosphino)ferrocene, palladium(II) acetate, triethylamine and a C₁₋₆ alkanol such as methanol, in an atmosphere of carbon monoxide. A compound of formula I wherein 25 Z-E- represents C₂₋₆ alkoxy carbonyl, e.g. methoxycarbonyl, may be converted to the corresponding compound of formula I wherein Z-E- represents carboxamido by treatment with ammonium chloride in the presence of trimethylaluminium.

Where the above-described processes for the preparation of the 30 compounds of use in the invention give rise to mixtures of stereoisomers, these isomers may be separated by conventional techniques such as

preparative chromatography. The compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The compounds may, for example, be resolved into their component enantiomers by standard techniques such as

5 preparative HPLC, or the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-*p*-toluoyl-d-tartaric acid and/or (+)-di-*p*-toluoyl-l-tartaric acid, followed by fractional crystallization and regeneration of the free base. The compounds may also be resolved by formation of diastereomeric esters or amides, followed by

10 chromatographic separation and removal of the chiral auxiliary.

During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in *Protective Groups in Organic Chemistry*, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, *Protective Groups in Organic Synthesis*, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

The following Examples illustrate the preparation of compounds of

20 use in the invention.

The compounds in accordance with this invention potently inhibit [³H]-ketanserin binding to the human 5-HT_{2A} receptor expressed in clonal cell lines. Moreover, those compounds of the invention which have been tested display a selective affinity for the 5-HT_{2A} receptor relative to the

25 dopamine D₂ receptor.

The compounds of the accompanying Examples were all found to possess a K_i value for displacement of [³H]-ketanserin from the human 5-HT_{2A} receptor, when expressed in Chinese hamster ovary (CHO) clonal cell lines, of 100 nM or less.

EXAMPLE 14-(4-Cyanophenylsulphonyl)-1-[2-(2,4-difluorophenyl)ethyl]piperidine5 a) N-BOC 4-mesyloxypiperidine

A solution of methanesulphonyl chloride (20 ml, 0.26 mol) in CH₂Cl₂ (200 ml) was added dropwise over 15 min to a solution of N-BOC 4-piperidinol (46 g, 0.23 mol) and Et₃N (64 ml, 0.46 mol) in CH₂Cl₂ (430ml) cooled below 7°C using a salt/ice bath. After addition was complete, stirring was continued for 15 min. The reaction was warmed to room temperature and quenched with 1N HCl (200 ml). The organic phase was washed with further 1N HCl (200 ml), brine (50 ml), 1N NaOH (100 ml), dried (MgSO₄) and evaporated to give 60 g (94% yield) of product as a colourless solid. δ_H (360MHz, CDCl₃) 1.46 (9H, s), 1.75-1.85 (2H, m), 1.90-2.00 (2H, m), 3.0 (3H, s), 3.25-3.35 (2H, m), 3.65-3.75 (2H, m), 4.85-4.95 (1H, m).

b) N-BOC 4-(4-bromophenylthio)piperidine

N-BOC 4-mesyloxypiperidine (40 g, 0.14 mol), 4-bromothiophenol (32 g, 0.17 mol) and potassium carbonate (30 g, 0.22 mol) were mixed at room temperature in CH₃CN (300 ml) and heated at reflux for 18 h. Work-up by partitioning between water and EtOAc afforded 50 g of material as a yellow oil. δ_H (360MHz, CDCl₃) 1.44 (9H, s), 1.45-1.55 (2H, m), 1.85-1.95 (2H, m), 2.85-2.95 (2H, m), 3.10-3.20 (1H, m), 3.95-4.05 (2H, m), 7.25-7.30 (2H, m), 7.40-7.45 (2H, m).

c) N-BOC 4-(4-bromophenylsulphonyl)piperidine

Water (26 ml) was added to alumina (130 g) which was slurried (5 min) and chloroform (500 ml) added followed by a solution of N-BOC 4-(4-bromophenylthio)piperidine (50 g, 0.13 mol) in chloroform (300 ml). Oxone (250 g, 0.39 mol) was added and the resulting slurry stirred and heated at

reflux for 18 h. After cooling to room temperature the mixture was filtered and the mother liquor washed with water, dried (MgSO_4) and evaporated to give the product as a colourless solid. δ_{H} (360MHz, CDCl_3) 1.43 (9H, s), 1.50-1.70 (2H, m), 1.90-2.00 (2H, m), 2.55-2.70 (2H, m), 2.90-3.10 (1H, m), 5 4.15-4.25 (2H, m), 7.73 (4H, s).

d) 4-(4-Bromophenylsulphonyl)piperidine

N-BOC 4-(4-bromophenylsulphonyl)piperidine (63 g, 0.156 mol) was dissolved in methanol (300 ml) and 5N HCl (63 ml) and heated at reflux 10 for 3 h. After a warm filtration to remove insolubles the solution was cooled to afford crystalline HCl salt (15.4 g) which was collected by filtration. Neutralisation of the mother liquor with sodium carbonate and extraction with CH_2Cl_2 afforded 16 g of additional material, a colourless solid, as the free base. Hydrochloride: δ_{H} (400MHz, DMSO-d_6) 1.65-1.80 15 (2H, m), 1.95-2.05 (2H, m), 1.80-2.90 (2H, m), 3.25-3.35 (2H, m), 3.60-3.70 (1H, m), 7.80 (2H, d, J 8Hz), 7.90 (2H, d, J 8Hz). Free base: δ_{H} (360MHz, CDCl_3) 1.45-1.60 (2H, m), 1.95-2.00 (2H, m), 2.50-2.60 (2H, m), 2.95-3.05 (1H, m), 3.15-3.25 (2H, m), 7.70 (4H, s).

20 e) 4-(4-Bromophenylsulphonyl)-1-[2-(2,4-difluorophenyl)ethyl]piperidine

A mixture of 4-(4-bromophenylsulphonyl)piperidine (7.6 g, 0.025 mol), 2,4-difluorophenethyl bromide (8.3 g, 0.38 mol), potassium carbonate (7.5 g, 0.054 mol) and sodium iodide (5.6 g, 0.037 mol) in CH_3CN (70 ml) was heated at reflux under nitrogen for 18 h. The reaction mixture was 25 then concentrated and partitioned between water and EtOAc. The organic phase was washed with brine, dried (Na_2SO_4) and concentrated.

Trituration with hexane gave 6.5 g of product as a colourless solid. δ_{H} (360MHz, CDCl_3) 1.55-1.75 (2H, m), 1.95-2.05 (4H, m), 2.45-2.55 (2H, m), 2.70-2.75 (2H, m), 2.85-2.95 (1H, m), 3.05-3.10 (2H, m), 6.70-6.85 (2H, m), 30 7.10-7.15 (1H, m), 7.72 (4H, s).

f) 4-(4-Cyanophenylsulphonyl)-1-[2-(2,4-difluorophenyl)ethyl]piperidine

A mixture of 4-(4-bromophenylsulphonyl)-1-[2-(2,4-difluorophenyl)ethyl]piperidine (2.2 g, 4.9 mmol) and copper(I) cyanide (2.3 g, 25 mmol) in NMP (3 ml) was heated under nitrogen at 160°C for 16 h while stirring. The hot solution was poured into water/CH₂Cl₂ (100/200 ml), the organic phase was washed with water, dried (Na₂SO₄) and evaporated to yield a syrup. Column chromatography [silica, petrol/ethyl acetate (1:1)] followed by recrystallisation from ethyl acetate yielded 1.05 g of crystalline material. δ_H (360MHz, CDCl₃) 1.56-1.76 (2H, m), 1.97-2.04 (4H, m), 2.50-2.54 (2H, m), 2.71-2.75 (2H, m), 2.90-2.97 (1H, m), 3.05-3.10 (2H, m), 6.72-6.80 (2H, m), 7.08-7.12 (1H, m), 7.87-7.89 (2H, m), 7.99-8.02 (2H, m).

Following Example 1 Steps a-e, using the appropriate thiophenol in Step b, the following Examples were prepared:

EXAMPLE 2

20 4-(4-Acetylaminophenylsulphonyl)-1-[2-(2,4-difluorophenyl)ethyl]piperidine

δ_H (360MHz, CDCl₃) 1.55-1.78 (2H, m), 1.96-2.05 (4H, m), 2.22 (3H, s), 2.49-2.52 (2H, m), 2.71-2.75 (2H, m), 2.84-2.92 (1H, m), 3.03-3.08 (2H, m), 6.71-6.80 (2H, m), 7.08-7.15 (1H, m), 7.70-7.79 (4H, m), 7.89 (1H, s).

25 EXAMPLE 3

4-(4-Cyano-3-fluorophenylsulphonyl)-1-[2-(2,4-difluorophenyl)ethyl]piperidine

30 δ_H (400MHz, CDCl₃) 1.68-1.79 (2H, m), 1.98-2.04 (4H, m), 2.51-2.55 (2H, m), 2.71-2.75 (2H, m), 2.91-2.99 (1H, m), 3.06-3.09 (2H, m), 6.73-6.81 (2H, m), 7.09-7.14 (1H, m), 7.75-7.81 (2H, m), 7.85-7.89 (1H, m).

EXAMPLE 4

5 1-[2-(2,4-Difluorophenyl)ethyl]-4-[4-(1,2,4-triazol-1-yl)phenylsulphonyl]-piperidine

A mixture of 1,2,4-triazole (0.175 g, 2.5 mmol), 4-(4-bromophenylsulphonyl)-1-[2-(2,4-difluorophenyl)ethyl]piperidine (0.54 g, 1.2 mmol), copper bronze (80 mg) and sodium hydride (60%, 100 mg, 2.5 mmol) in NMP (3 ml) was heated under nitrogen at 160°C for 16 h while stirring. The hot solution was poured into water/CH₂Cl₂ (10/20 ml) and further extracted into CH₂Cl₂. The combined organic phase was washed with water, dried (Na₂SO₄) and evaporated to yield a syrup. Column chromatography [silica, hexane/EtOAc (1:1)] yielded 250 mg of crystalline material. δ_H (360MHz, CDCl₃) 1.68-1.79 (2H, m), 1.98-2.05 (4H, m), 2.50-2.54 (2H, m), 2.71-2.75 (2H, m), 2.90-2.99 (1H, m), 3.05-3.09 (2H, m), 6.72-6.81 (2H, m), 7.09-7.15 (1H, m), 7.93-8.04 (4H, m), 8.17 (1H, s), 8.72 (1H, s).

20 Following Example 4, using the appropriate heterocycle, the following Examples were prepared:

EXAMPLE 5

25 1-[2-(2,4-Difluorophenyl)ethyl]-4-[4-(imidazol-1-yl)phenylsulphonyl]-piperidine

δ_H (360MHz, CDCl₃) 1.66-1.80 (2H, m), 1.94-2.12 (4H, m), 2.46-2.58 (2H, m), 2.66-2.78 (2H, m), 2.88-2.98 (1H, m), 3.02-3.14 (2H, m), 6.68-6.84 (2H, m), 7.06-7.18 (1H, m), 7.33-7.40 (1H, s), 7.56-7.64 (2H, m), 7.92-8.06 (4H, m).

EXAMPLE 61-[2-(2,4-Difluorophenyl)ethyl]-4-[4-(pyrazol-1-yl)phenylsulphonyl]-piperidine

5 δ_H (360MHz, CDCl₃) 1.67-1.82 (2H, m), 1.93-2.09 (4H, m), 2.46-2.57
(2H, m), 2.67-2.78 (2H, m), 2.86-2.98 (1H, m), 3.02-3.12 (2H, m), 6.52-6.58
(1H, s), 6.68-6.82 (2H, m), 7.06-7.18 (1H, m), 7.76-7.82 (1H, s), 7.86-7.98
(4H, m), 7.98-8.06 (1H, s).

10

EXAMPLE 71-[2-(2,4-Difluorophenyl)ethyl]-4-[4-(1,2,3-triazol-1-yl)phenylsulphonyl]-piperidine

15 δ_H (360MHz, CDCl₃) 1.66-1.82 (2H, m), 1.94-2.10 (4H, m), 2.48-2.56
(2H, m), 2.69-2.77 (2H, m), 2.89-3.02 (1H, m), 3.02-3.12 (2H, m), 6.69-6.83
(2H, m), 7.06-7.16 (1H, m), 7.86-7.94 (1H, s), 7.94-8.07 (4H, m), 8.07-8.12
(1H, m).

EXAMPLE 8

20

4-(4-Carboxamidophenylsulphonyl)-1-[2-(2,4-difluorophenyl)ethyl]-piperidine

25 A solution of 4-(4-cyanophenylsulphonyl)-1-[2-(2,4-difluorophenyl)-ethyl]piperidine (0.5 g, 1.28 mmol) (Example 1) in 85% H₂SO₄ (10 ml) was heated at 100°C for 30 min. The cooled solution was diluted with water (40 ml) and neutralized with solid KOH. At pH 7 a precipitate was collected and dissolved in CH₂Cl₂. The organic phase was dried (MgSO₄) and concentrated to yield the title compound, m.p. 195-197°C (softens 186-189°C). δ_H (360MHz, CDCl₃) 1.70-1.77 (2H, m), 1.97-2.03 (4H, m), 2.50-
30 2.54 (2H, m), 2.71-2.75 (2H, m), 2.89-2.92 (1H, m), 3.04-3.07 (2H, m), 5.74
(1H, s), 6.15 (1H, s), 6.73-6.80 (2H, m), 7.08-7.12 (1H, m), 7.94-8.00 (4H, s).

EXAMPLE 9

5 4-(4-Carboxamido-3-fluorophenylsulphonyl)-1-[2-(2,4-difluorophenyl)-ethyl]piperidine

A mixture of 4-(4-cyano-3-fluorophenylsulphonyl)-1-[2-(2,4-difluorophenyl)ethyl]piperidine (0.095 g, 0.52 mmol) (Example 3) and 85% H₂SO₄ (0.1 ml) was irradiated in a screw-capped tube using microwave radiation at 50 W for 1.5 minutes under nitrogen. To the resulting 10 solution was added water (0.5 ml), saturated Na₂CO₃ (1 ml) and CH₂Cl₂ (2 ml) and the mixture transferred into a separating funnel. The aqueous phase was extracted with further portions of CH₂Cl₂ and the combined organic solutions washed with brine, dried (Na₂SO₄) and evaporated to yield a solid. Recrystallisation from EtOAc yielded 36 mg of a crystalline 15 solid. δ_H (400MHz, CDCl₃) 1.68-1.79 (2H, m), 1.97-2.03 (4H, m), 2.50-2.54 (2H, m), 2.71-2.75 (2H, m), 2.90-2.98 (1H, m), 3.06-3.09 (2H, m), 5.99 (1H, s), 6.66-6.67 (1H, m), 6.73-6.81 (2H, m), 7.09-7.15 (1H, m), 7.68-7.71 (1H, m), 7.77-7.79 (1H, m), 8.31-8.35 (1H, m).

20

EXAMPLE 10

1-[2-(2,4-Difluorophenyl)ethyl]-4-[4-(2-methyltetrazol-5-yl)-phenylsulphonyl]piperidine

A mixture of 4-(4-bromophenylsulphonyl)-1-[2-(2,4-difluorophenyl)ethyl]piperidine (0.38 g, 0.86 mmol), 2-methyl-5-(tributylstannylyl)tetrazole (0.64 g, 1.72 mmol) and tetrakis(triphenylphosphine)palladium (100 mg, 0.02 mmol) in DMF was heated at 110°C for 16 hours while stirring under nitrogen. The solution was poured into water/EtOAc (5/20 ml) and further extracted into EtOAc. 30 The combined organic phase was washed with water, dried (Na₂SO₄) and evaporated to yield a syrup. Column chromatography (silica, EtOAc)

followed by recrystallisation from EtOAc yielded 220 mg of crystalline material. δ_H (400MHz, CDCl₃) 1.73-1.80 (2H, m), 1.98-2.06 (4H, m), 2.50-2.54 (2H, m), 2.71-2.75 (2H, m), 2.92-2.98 (1H, m), 3.05-3.08 (2H, m), 4.45 (3H, s), 6.71-6.80 (2H, m), 7.09-7.14 (1H, m), 7.99 (1H, d, J 5.2Hz), 8.34 (1H, d, J 5.2Hz).

EXAMPLE 11

10 1-[2-(2,4-Difluorophenyl)ethyl]-4-[4-(1-methyl-1,2,4-triazol-5-yl)-phenylsulphonyl]piperidine

This compound was prepared analogously to Example 10 using 1-methyl-5-(tributylstannyl)-1,2,4-triazole. δ_H (400MHz, CDCl₃) 1.70-1.80 (2H, m), 1.98-2.06 (4H, m), 2.51-2.55 (2H, m), 2.72-2.75 (2H, m), 2.92-2.98 (1H, m), 3.06-3.09 (2H, m), 4.06 (3H, s), 6.72-6.80 (2H, m), 7.09-7.12 (1H, m), 7.99-8.02 (2H, d, J 1.5Hz), 8.02 (1H, s), 8.03-8.04 (2H, d, J 1.5Hz).

EXAMPLE 12

20 1-[2-(2,4-Difluorophenyl)ethyl]-4-[4-(tetrazol-1-ylmethyl)phenylsulphonyl]piperidine

a) 1-[2-(2,4-Difluorophenyl)ethyl]-4-(4-methoxycarbonylphenylsulphonyl)piperidine

25 4-(4-Bromophenylsulphonyl)-1-[2-(2,4-difluorophenyl)ethyl]-piperidine (2 g, 4.5 mmol) was stirred with Et₃N (1.25 ml, 9 mmol), 1,1'-bis(diphenylphosphino)ferrocene (0.15 g, 2.7 mmol) and Pd(OAc)₂ (0.03 g, 1.34 mmol) in a mixture of MeOH (10 ml) and DMF (20 ml) at 60°C. The mixture was allowed to stir at 60°C under an atmosphere of carbon monoxide for 5 days, cooled to room temperature and concentrated. The residue was dissolved in CH₂Cl₂ and washed with water. The organic layer was dried (MgSO₄) and purified by column chromatography (SiO₂,

EtOAc:pet. ether 60-80° 1:1) to give the product as a white solid, m.p. 123-124°C. (Found: C, 59.78; H, 5.52; N, 3.37. C₂₁H₂₃F₂NO₄S requires C, 59.56; H, 5.47; N, 3.31). δ_H (360MHz, CDCl₃) 1.66-1.80 (2H, m), 1.96-2.02 (4H, m), 2.49-2.55 (2H, m), 2.72-2.78 (2H, m), 2.87-2.98 (1H, m), 3.03-3.10 (2H, m), 5 3.98 (3H, s), 6.71-6.81 (2H, m), 7.08-7.14 (1H, m), 7.96 (2H, d, J 8Hz), 8.22 (2H, d, J 8Hz).

b) 1-[2-(2,4-Difluorophenyl)ethyl]-4-(4-hydroxymethylphenylsulphonyl)piperidine

10 1-[2-(2,4-Difluorophenyl)ethyl]-4-(4-methoxycarbonylphenylsulphonyl)piperidine (0.6 g, 1.42 mmol) was dissolved in anhydrous CH₂Cl₂ (15 ml) and stirred under nitrogen at -78°C. DIBAL-H (1M in THF, 4.25 ml, 4.25 mmol) was added dropwise. The reaction mixture was stirred at -78°C for 15 min, allowed to warm up to room temperature and 15 stirred for 1 h. Crushed Na₂SO₄.10H₂O (5 eq.) was added and the mixture left at room temperature overnight. Inorganic solid was filtered off and washed with CH₂Cl₂ and EtOAc. The organic filtrate was concentrated to give a beige solid. δ_H (360MHz, CDCl₃) 1.64-1.77 (2H, m), 1.94-2.06 (4H, m), 2.47-2.55 (2H, m), 2.70-2.76 (2H, m), 2.83-2.94 (2H, m), 3.02-3.08 (2H, m), 4.82 (2H, s), 6.71-6.82 (2H, m), 7.06-7.14 (1H, m), 7.55 (2H, d, 8Hz), 20 7.85 (2H, d, 8Hz).

c) 1-[2-(2,4-Difluorophenyl)ethyl]-4-[4-(tetrazol-1-ylmethyl)phenylsulphonyl]piperidine

25 1-[2-(2,4-Difluorophenyl)ethyl]-4-(4-hydroxymethylphenylsulphonyl)piperidine (0.20 g, 0.51 mmol) was dissolved in anhydrous THF (10 ml) under nitrogen at 0°C. Et₃N (0.14 ml, 1 mmol) and methanesulphonyl chloride (0.078 ml, 1 mmol) were added dropwise. The mixture was stirred at room temperature for 1 h, quenched with water and 30 extracted into EtOAc. The organic extracts were combined, washed with water, dried (MgSO₄) and solvent evaporated. The residue was dissolved

in IPA (20 ml), and heated to reflux overnight with NaI (0.076 g), Cs₂CO₃ (0.197 g) and 1*H*-tetrazole (1.06 g, 15 mmol). The reaction mixture was cooled to room temperature and concentrated. The residue was partitioned between water and CH₂Cl₂ and the organic layer was washed 5 with water, dried (MgSO₄) and concentrated. Purification by column chromatography (SiO₂; EtOAc:pet. ether 60-80° 1:1 to EtOAc:MeOH 99:1) gave the *title compound*, m.p. 168-169°C. (Found: C, 56.00; H, 4.91; N, 15.82. C₂₁H₂₃N₅O₂SF₂ requires C, 56.36; H, 5.18; N, 15.63). δ_H (360MHz, CDCl₃) 1.64-1.77 (2H, m), 1.97-2.05 (4H, m), 2.48-2.53 (2H, m), 2.70-2.76 10 (2H, m), 2.86-2.95 (1H, m), 3.01-3.10 (2H, m), 5.71 (2H, s), 6.72-6.80 (2H, m), 7.08-7.15 (1H, m), 7.46 (2H, d, J 8Hz), 7.91 (2H, d, J 8Hz), 8.65 (1H, s).

EXAMPLE 13

15 4-(4-Carboxamidophenylsulphonyl)-1-(2-phenylethyl)piperidine

a) 4-(4-Bromophenylsulphonyl)-1-phenylacetamidopiperidine

A solution of 4-(4-bromophenylsulphonyl)piperidine (Example 1, Step d) (1.0 g, 3.3 mmol), phenylacetic acid (674 mg, 5.0 mmol) and 20 triethylamine (0.92 ml, 6.6 mmol) were stirred in CH₂Cl₂ (10 ml) under a nitrogen atmosphere. Bis(2-oxo-3-oxazolidinyl)phosphinic chloride (1.25 g, 4.9 mmol) was added in portions and the reaction allowed to stir for 18 h. The reaction was washed sequentially with 1N HCl, saturated Na₂CO₃, brine and dried (MgSO₄). Concentration *in vacuo* gave the product as a 25 colourless solid. δ_H (360MHz, CDCl₃) 1.10-1.26 (1H, m), 1.40-1.55 (1H, m), 1.90-2.04 (2H, m), 2.48-2.55 (1H, m), 2.89-2.96 (1H, m), 3.00-3.10 (1H, m), 3.70-3.74 (2H, m), 3.94-3.98 (1H, m), 4.73-4.77 (1H, m), 7.15-7.17 (2H, m), 7.24-7.30 (3H, m), 7.63 (2H, d, J 6.48Hz), 7.71 (2H, d, J 6.48Hz).

b) 4-(4-Bromophenylsulphonyl)-1-(2-phenylethyl)piperidine

A suspension of the foregoing product (1.18 g, 2.8 mmol) in 20 ml anhydrous THF was stirred under a nitrogen atmosphere. BH₃:THF (13.9 ml of a 1.0M solution) was added and the reaction heated to reflux for 6 h.

5 The reaction was allowed to cool, 6N HCl (50 ml) was added and the reaction allowed to stand for 18 h. The reaction was basified using 4N NaOH and extracted into CH₂Cl₂. The organic phase was washed with brine, dried (Na₂SO₄) and concentrated. Purification using dry flash column chromatography with 3% MeOH-CH₂Cl₂ as eluent gave the product

10 as a solid. *m/z* (ES⁺) 408 and 410 (M + H⁺).

c) 4-(Carboxamidophenylsulphonyl)-1-(2-phenylethyl)piperidine

A suspension of the preceding product (0.86 g, 2.1 mmol) in 20 ml anhydrous DMF was degassed by passing a stream of nitrogen through for 15 minutes. Palladium(II) acetate (52 mg) and 1,3-bis(diphenyl-phosphino)propane (100 mg) were added. The reaction was purged with carbon monoxide before 1,1,1,3,3,3-hexamethyldisilazane (3.1 ml) and diisopropylamine (0.73 ml) were added. The reaction was heated to 100°C under a CO atmosphere for 18 h. The reaction was allowed to cool and 20 treated with 5N HCl (100 ml) for 4 h. The reaction was extracted with Et₂O. The aqueous phase was basified with 4N NaOH and extracted with Et₂O and then EtOAc. The combined organic phases were dried (Na₂SO₄), and concentrated to give the *title compound*, m.p. 202-204°C (MeOH). (Found: C, 64.06; H, 6.24; N, 7.14. C₂₀H₂₄N₂O₃S requires C, 64.49; H, 6.49; 25 N, 7.52). δ_H (400MHz, CDCl₃) 1.67-1.78 (2H, m), 1.95-2.03 (4H, m), 2.54-2.58 (2H, m), 2.71-2.75 (2H, m), 2.89-2.97 (1H, m), 3.06-3.09 (2H, m), 6.00 (2H, br d, J 180Hz), 7.14-7.20 (3H, m), 7.24-7.28 (2H, m), 7.94-7.99 (4H, m).

30 The following Examples were prepared, using the appropriate substituted phenylacetic acids, by the method described for Example 13:

EXAMPLE 144-(4-Carboxamidophenylsulphonyl)-1-[2-(4-fluorophenyl)ethyl]piperidine

5 Free base: m.p. 196-197°C. δ_H (400MHz, CDCl₃) 1.69-1.77 (2H, m),
1.98-2.00 (4H, m), 2.52-2.54 (2H, m), 2.69-2.71 (2H, m), 2.90-2.93 (1H, m),
3.06-3.09 (2H, m), 5.68 (1H, s), 6.08 (1H, s), 6.95-6.97 (2H, m), 7.09-7.11
(2H, m), 7.98 (4H, s).

10

EXAMPLE 154-(4-Carboxamidophenylsulphonyl)-1-[2-(2-chlorophenyl)ethyl]piperidine

Free base: δ_H (400MHz, CDCl₃) 1.70-1.78 (2H, m), 2.00-2.04 (4H, m),
2.52-2.58 (2H, m), 2.83-2.92 (3H, m), 3.07-3.10 (2H, m), 5.70 (1H, s), 6.10
15 (1H, s), 7.10-7.16 (3H, m), 7.18-7.21 (1H, m), 7.98 (4H, s).

EXAMPLE 164-(4-Carboxamidophenylsulphonyl)-1-(2-fluoro-2-phenylethyl)piperidine

20

a) 4-(4-Bromophenylsulphonyl)-1-(2-fluoro-2-phenylethyl)piperidine

4-(4-Bromophenylsulphonyl)piperidine (0.7 g, 2.3 mmol) was reacted with α -fluorophenylacetic acid (0.53 g, 3.45 mmol) in a similar manner as described for Example 13, Steps a and b, to give the required product as a colourless solid, 0.56 g (58%), m.p. 126-127°C (EtOAc-pet. ether 60-80°). δ_H (400MHz, CDCl₃) 1.70-1.77 (2H, m), 2.00-2.03 (2H, m), 2.13-2.20 (2H, m),
25 2.57-2.69 (1H, m), 2.83-2.93 (2H, s), 3.04-3.18 (2H, m), 5.51-5.65 (1H, m),
7.28-7.39 (5H, m), 7.70-7.75 (4H, m).

b) 4-(4-Cyanophenylsulphonyl)-1-(2-fluoro-2-phenylethyl)piperidine

4-(4-Bromophenylsulphonyl)-1-(2-fluoro-2-phenylethyl)piperidine (0.69 g, 1.6 mmol) was dissolved in DMF (15 ml), and stirred with zinc cyanide (0.21 g, 1.79 mmol). The mixture was purged with nitrogen gas, 5 tetrakis(triphenylphosphine)palladium(0) (80 mg) was added and the mixture heated at 80°C for 4 hours. After cooling to room temperature, 10% aqueous NH₄OH solution was added and the mixture was extracted with EtOAc. The organic extracts were combined, washed with saturated brine, water, dried (MgSO₄) and concentrated. The product was purified by column chromatography (SiO₂; MeOH:CH₂Cl₂ 2:98) to give the product as a colourless solid, m.p. 171°C (EtOAc-pet. ether 60-80°). (Found: C, 64.36; H, 5.59; N, 7.37. C₂₀H₂₁F₂N₂O₂S requires C, 64.50; H, 5.68; N, 7.52). δ_H (400MHz, CDCl₃) 1.70-1.82 (2H, m), 1.99-2.02 (2H, m), 2.15-2.21 (2H, m), 2.57-2.70 (1H, m), 2.83-2.98 (2H, m), 2.05-3.08 (1H, m), 3.16-3.19 (1H, m), 5.50-5.65 (1H, m), 7.28-7.38 (5H, m), 7.87-7.89 (2H, d, J 8Hz), 7.90-8.02 (2H, d, J 8Hz).

c) 4-(4-Carboxamidophenylsulphonyl)-1-(2-fluoro-2-phenylethyl)piperidine

4-(4-Cyanophenylsulphonyl)-1-(2-fluoro-2-phenylethyl)piperidine (0.050 mg, 0.134 mmol) was dissolved in anhydrous THF (2 ml), and treated with potassium trimethylsilylolate (0.035 g, 0.369 mmol). The mixture was heated to reflux and the resultant precipitate was filtered off, dissolved in CH₂Cl₂, washed with water, dried (MgSO₄), and concentrated to give the *title compound* as a colourless solid, m.p. 192°C. δ_H (400MHz, CDCl₃) 1.73-1.79 (2H, m), 1.99-2.03 (2H, m), 2.13-2.20 (2H, m), 2.56-2.96 (1H, m), 3.04-3.07 (1H, m), 3.15-3.18 (1H, m), 5.50-5.65 (1H, m), 7.26-7.38 (5H, m), 7.96-8.01 (4H, m).

EXAMPLE 171-[2-(2,4-Difluorophenyl)ethyl]-4-phenylsulphonylpiperidine

This compound was prepared following Example 1 Steps a-e using
5 thiophenol in place of 4-bromothiophenol in Step b. δ_H (360MHz, CDCl₃)
1.66-1.74 (2H, m), 1.96-2.04 (4H, m), 2.49-2.53 (2H, m), 2.71-2.75 (2H, m),
2.86-2.94 (1H, m), 3.04-3.08 (2H, m), 6.72-6.80 (2H, m), 7.09-7.14 (1H, m),
7.55-7.59 (2H, m), 7.64-7.68 (1H, s), 7.87-7.89 (2H, m).

10

EXAMPLE 184-(3-Carboxamidophenylsulphonyl)-1-[2-(2,4-difluorophenyl)ethyl]-piperidine15 a) 4-(3-Bromophenylsulphonyl)-1-[2-(2,4-difluorophenyl)ethyl]piperidine

This compound was prepared following Example 1 Steps a-e using
3-bromothiophenol in place of 4-bromothiophenol in Step b. δ_H (360MHz,
CDCl₃) 1.66-1.74 (2H, m), 1.98-2.03 (4H, m), 2.50-2.54 (2H, m), 2.71-2.75
(2H, m), 2.87-2.94 (1H, m), 3.05-3.08 (2H, m), 6.72-6.80 (2H, m), 7.09-7.17
20 (1H, m), 7.45 (1H, t, 7.8Hz), 7.78-7.82 (2H, m), 8.01-8.02 (1H, m).

b) 1-[2-(2,4-Difluorophenyl)ethyl]-4-(3-methoxycarbonylphenylsulphonyl)-piperidine

Carbon monoxide was bubbled through a solution of 4-(3-bromophenylsulphonyl)-1-[2-(2,4-difluorophenyl)ethyl]piperidine (3.95 g, 0.009 mol), Et₃N (2.5 ml, 0.018 mol), palladium(II) acetate (0.06 g, 0.0003 mol) and 1,1'-bis(diphenylphosphino)ferrocene (0.3 g, 0.0005 mol) in a mixture of methanol (30 ml) and DMF (30 ml) at room temperature. The mixture was heated at 60°C for 18 h and then partitioned between ethyl acetate and water. Product from the organic phase was purified by column chromatography (SiO₂, EtOAc:pet. ether 60-80°C 1:1) to give 2.75 g

(73% yield) of material as a colourless solid, m.p. 116-117°C. δ_H (360MHz, CDCl₃) 1.72-1.77 (2H, m), 1.97-2.03 (4H, m), 2.49-2.54 (2H, m), 2.70-2.75 (2H, m), 2.90-2.94 (1H, m), 3.04-3.07 (2H, m), 3.97 (3H, s), 6.72-6.80 (2H, m), 7.08-7.12 (1H, m), 7.67 (1H, t, 7.8Hz), 8.07-8.50 (1H, m), 8.24-8.32 (1H, m), 8.55 (1H, s).

c) 4-(3-Carboxamidophenylsulphonyl)-1-[2-(2,4-difluorophenyl)ethyl]piperidine

A solution of 1-[2-(2,4-difluorophenyl)ethyl]-4-(3-methoxycarbonylphenylsulphonyl)piperidine (0.2 g, 0.00047 mol) in toluene (10 ml) was added to a mixture of trimethylaluminium (0.71 ml, 0.0014 mol) and ammonium chloride (0.077 g, 0.0014 mol) in toluene (8 ml) at 0°C. The mixture was heated at reflux for 18 h, cooled to room temperature and quenched with 2N HCl, basified with 2N NaOH and extracted with CH₂Cl₂. The crude product obtained from the organic phase was purified by column chromatography (SiO₂, CH₂Cl₂:MeOH 97:3) to give 41 mg (21% yield) of product, m.p. 142-143°C. δ_H (400MHz, CDCl₃) 1.68-1.78 (2H, m), 1.97-2.02 (4H, m), 2.50-2.54 (2H, m), 2.71-2.75 (2H, m), 2.90-3.00 (1H, m), 3.04-3.07 (2H, m), 5.75-5.85 (1H, s), 6.20-6.30 (1H, s), 6.70-6.80 (2H, m), 7.10-7.15 (1H, m), 7.70 (1H, t, 7.8Hz), 8.05 (1H, d, 7.8Hz), 8.15 (1H, d, 7.8Hz), 8.28 (1H, s).

EXAMPLE 19

25 4-(4-Bromophenylsulphonyl)-1-[2-(4-fluorophenyl)-2-oxoethyl]piperidine

4-(4-Bromophenylsulphonyl)piperidine (Example 1 Step d, 0.9 g, 0.003 mol) was added to a mixture of 2-bromo-4'-fluoroacetophenone (0.7 g, 0.0033 mol) and potassium carbonate (0.84 g, 0.006 mol) in acetonitrile (5 ml) and the resulting slurry stirred at room temperature for 17 h. The insolubles were removed by filtration and the solvent evaporated to give a gum which was purified by column chromatography (SiO₂, CH₂Cl₂:MeOH

97:3) to give 0.5 g (36% yield) of product as a colourless solid. δ_H (400MHz, CDCl₃) 1.75-1.90 (2H, m), 2.05-2.13 (2H, m), 2.25-2.40 (2H, m), 2.85-3.00 (1H, m), 3.04-3.20 (2H, m), 3.75-3.85 (2H, m), 7.12 (1H, t, 8Hz), 7.24 (4H, s), 7.98-8.02 (2H, m).

5

EXAMPLE 20

4-(4-Cyanophenylsulphonyl)-1-[2-(4-fluorophenyl)-2-oxoethyl]piperidine

This compound was prepared following Example 1 Step f using 4-(4-bromophenylsulphonyl)-1-[2-(4-fluorophenyl)-2-oxoethyl]piperidine (Example 19) in place of 4-(4-bromophenylsulphonyl)-1-[2-(2,4-difluorophenyl)ethyl]piperidine. δ_H (360MHz, CDCl₃) 1.75-1.86 (2H, m), 2.00-2.04 (2H, m), 2.19-2.25 (2H, m), 2.93-3.01 (1H, m), 3.06-3.09 (2H, m), 3.76 (2H, s), 7.12 (2H, t, 8Hz), 7.87 (2H, d, 8Hz), 7.98-8.01 (4H, m).

15

EXAMPLE 21

1-[2-(4-Fluorophenyl)-2-oxoethyl]-4-phenylsulphonylpiperidine

This compound was prepared following Example 19 using 4-phenylsulphonylpiperidine in place of 4-(4-bromophenylsulphonyl)piperidine. δ_H (400MHz, CDCl₃) 1.75-1.85 (2H, m), 2.00-2.05 (2H, m), 2.19-2.22 (2H, m), 2.89-2.98 (1H, m), 3.05-3.08 (2H, m), 3.74 (2H, s), 7.12 (2H, t, 8Hz), 7.56 (2H, t, 8Hz), 7.65-7.69 (1H, m), 7.87 (2H, d, 8Hz), 7.98-8.02 (2H, m).

25

EXAMPLE 22


1-[2-(4-Chlorophenyl)-2-oxoethyl]-4-phenylsulphonylpiperidine

Prepared from 2-bromo-4'-chloroacetophenone utilising the method of Example 19. δ_H (400MHz, CDCl₃) 1.76-1.87 (2H, m), 2.04-2.07 (2H, m),

2.21-2.26 (2H, m), 2.90-2.98 (1H, m), 3.07-3.10 (2H, m), 3.77 (2H, s), 7.42 (2H, d, 8Hz), 7.56 (2H, t, 8Hz), 7.65-7.69 (1H, m), 7.86-7.93 (4H, m).

CLAIMS:

1. A compound of formula I, or a salt thereof:



5

(I)

wherein


Z represents hydrogen, halogen, cyano, nitro, trifluoromethyl, trifluoromethoxy, -OR^a, -SR^a, -SOR^a, -SO₂R^a, -SO₂NR^aR^b, -NR^aR^b,
10 -NR^aCOR^b, -NR^aCO₂R^b, -COR^a, -CO₂R^a or -CONR^aR^b; or
 Z represents an optionally substituted five-membered heteroaromatic ring selected from furan, thiophene, pyrrole, oxazole, thiazole, isoxazole, isothiazole, imidazole, pyrazole, oxadiazole, thiadiazole, triazole and tetrazole; or
 15 Z represents an optionally substituted six-membered heteroaromatic ring selected from pyridine, pyrazine, pyrimidine and pyridazine;
 R^a and R^b independently represent hydrogen or C₁₋₆ alkyl; or R^a and R^b, when linked through a nitrogen atom, together represent the residue of
20 an azetidine, pyrrolidine, piperidine or morpholine ring;
 E represents a chemical bond or a straight or branched alkylene chain containing from 1 to 4 carbon atoms, optionally incorporating an oxygen atom to form an ether linkage;
 M represents the residue of an azetidine, pyrrolidine or piperidine ring;
 25 R¹ represents an optionally substituted aryl(C₂₋₄)alkyl group; and

BNSDOCID: <WO_____0043362A1_I_>

R² represents hydrogen or halogen.

2. A compound as claimed in claim 1 represented by formula IB, or a salt thereof:


5



(IB)

wherein Z, E, R¹ and R² are as defined in claim 1.

10 3. A compound as claimed in claim 2 represented by formula IIA, and salts thereof:



(IIA)


15 wherein

Z and E are as defined in claim 1;

R¹¹ and R¹² independently represent hydrogen, halogen, nitro, trifluoromethyl, C₁₋₆ alkyl, hydroxy, C₁₋₆ alkoxy, C₁₋₆ alkylthio or di(C₁₋₆)alkylamino;

R^{13} represents hydrogen and R^{14} represents hydrogen or fluoro, or
 R^{13} and R^{14} together represent keto; and
 R^{21} represents hydrogen or fluoro.


5 4. A compound as claimed in claim 2 represented by formula IIB, and salts thereof:



(IIB)

10 wherein Z, E and R^1 are as defined in claim 1; and
 R^{21} is as defined in claim 3.

15 5. A compound as claimed in claim 3 or claim 4 represented by formula IIC, and salts thereof:



(IIC)

wherein Z and E are as defined in claim 1; and
 R^{11} , R^{12} , R^{13} , R^{14} and R^{21} are as defined in claim 3.

6. A compound selected from:

4-(4-cyanophenylsulphonyl)-1-[2-(2,4-difluorophenyl)ethyl]piperidine;

4-(4-acetylaminophenylsulphonyl)-1-[2-(2,4-difluorophenyl)ethyl]-
5 piperidine;

4-(4-cyano-3-fluorophenylsulphonyl)-1-[2-(2,4-difluorophenyl)ethyl]-
piperidine;

1-[2-(2,4-difluorophenyl)ethyl]-4-[4-(1,2,4-triazol-1-yl)phenylsulphonyl]-
piperidine;

10 1-[2-(2,4-difluorophenyl)ethyl]-4-[4-(imidazol-1-yl)phenylsulphonyl]-
piperidine;

1-[2-(2,4-difluorophenyl)ethyl]-4-[4-(pyrazol-1-yl)phenylsulphonyl]-
piperidine;

1-[2-(2,4-difluorophenyl)ethyl]-4-[4-(1,2,3-triazol-1-yl)phenylsulphonyl]-
15 piperidine;

4-(4-carboxamidophenylsulphonyl)-1-[2-(2,4-difluorophenyl)ethyl]-
piperidine;

4-(4-carboxamido-3-fluorophenylsulphonyl)-1-[2-(2,4-difluorophenyl)ethyl]-
piperidine;

20 1-[2-(2,4-difluorophenyl)ethyl]-4-[4-(2-methyltetrazol-5-yl)-
phenylsulphonyl]piperidine;

1-[2-(2,4-difluorophenyl)ethyl]-4-[4-(1-methyl-1,2,4-triazol-5-yl)-
phenylsulphonyl]piperidine;

1-[2-(2,4-difluorophenyl)ethyl]-4-[4-(tetrazol-1-ylmethyl)phenylsulphonyl]-
25 piperidine;

4-(4-carboxamidophenylsulphonyl)-1-(2-phenylethyl)piperidine;

4-(4-carboxamidophenylsulphonyl)-1-[2-(4-fluorophenyl)ethyl]piperidine;

4-(4-carboxamidophenylsulphonyl)-1-[2-(2-chlorophenyl)ethyl]piperidine;

4-(4-carboxamidophenylsulphonyl)-1-(2-fluoro-2-phenylethyl)piperidine;

30 1-[2-(2,4-difluorophenyl)ethyl]-4-phenylsulphonylpiperidine;
and salts thereof.

7. A compound selected from:

4-(3-carboxamidophenylsulphonyl)-1-[2-(2,4-difluorophenyl)ethyl]-
piperidine;

5 4-(4-bromophenylsulphonyl)-1-[2-(4-fluorophenyl)-2-oxoethyl]piperidine;
4-(4-cyanophenylsulphonyl)-1-[2-(4-fluorophenyl)-2-oxoethyl]piperidine;
1-[2-(4-fluorophenyl)-2-oxoethyl]-4-phenylsulphonylpiperidine;
1-[2-(4-chlorophenyl)-2-oxoethyl]-4-phenylsulphonylpiperidine;
and salts thereof.

10

8. A pharmaceutical composition comprising a compound of formula I as defined in claim 1 or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier.


15

9. The use of a compound of formula I as defined in claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment and/or prevention of a disorder for which a selective antagonist of the human 5-HT_{2A} receptor is indicated.

20

10. A process for the preparation of a compound as claimed in claim 1, which comprises:

(A) attachment of the R¹ moiety to a compound of formula III:




(III)

25

wherein Z, E, M and R² are as defined in claim 1; or

(B) oxidizing a compound of formula V:



5

(V)

wherein Z, E, M, R¹ and R² are as defined in claim 1; and

(C) subsequently, where required, converting a compound of formula I initially obtained into a further compound of formula I by conventional methods.

11. A method for the treatment and/or prevention of a disorder for which a selective antagonist of the human 5-HT_{2A} receptor is indicated, 15 which comprises administering to a patient in need of such treatment an effective amount of a compound of formula I as defined in claim 1, or a pharmaceutically acceptable salt thereof.

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/GB 00/00153

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07D211/54 C07D401/10 A61K31/445 A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DE 196 01 189 A (DEGUSSA) 17 July 1997 (1997-07-17) page 3, line 46 - line 49 ----	1,8,9,11
A	EP 0 304 888 A (EISAI CO LTD) 1 March 1989 (1989-03-01) page 32 -page 34 ----	1,8
A	US 5 753 679 A (RIEMER CLAUS) 19 May 1998 (1998-05-19) claim 1 ----	1,8
A	WO 96 35666 A (HOFFMANN LA ROCHE) 14 November 1996 (1996-11-14) cited in the application ----	1,8
A	US 4 218 455 A (FLYNN PATRICK F ET AL) 19 August 1980 (1980-08-19) -----	1,8

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
10 March 2000	22/03/2000
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer De Jong, B

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 00/00153

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 11 because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 11 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compounds.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat'l Application No

PCT/GB 00/00153

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
DE 19601189	A	17-07-1997	NONE		
EP 0304888	A	01-03-1989	JP 1052756 A JP 2637989 B JP 1052752 A JP 2110578 C JP 8019083 B JP 1052717 A JP 2584454 B AT 82263 T CA 1263658 A DE 3875866 A DK 470488 A ES 2045044 T GR 3006380 T HU 48587 A,B KR 9102581 B NO 883750 A PH 25458 A US 4977165 A US 5082850 A US 5162347 A US 5246946 A	28-02-1989 06-08-1997 28-02-1989 21-11-1996 28-02-1996 28-02-1989 26-02-1997 15-11-1992 05-12-1989 17-12-1992 25-02-1989 16-01-1994 21-06-1993 28-06-1989 27-04-1991 27-02-1989 01-07-1991 11-12-1990 21-01-1992 10-11-1992 21-09-1993	
US 5753679	A	19-05-1998	AU 5763096 A BR 9608328 A CA 2220504 A CN 1183768 A WO 9635666 A EP 0871613 A JP 10506637 T	29-11-1996 23-02-1999 14-11-1996 03-06-1998 14-11-1996 21-10-1998 30-06-1998	
WO 9635666	A	14-11-1996	AU 5763096 A BR 9608328 A CA 2220504 A CN 1183768 A EP 0871613 A JP 10506637 T US 5753679 A	29-11-1996 23-02-1999 14-11-1996 03-06-1998 21-10-1998 30-06-1998 19-05-1998	
US 4218455	A	19-08-1980	NONE		

THIS PAGE BLANK (USP 70)